Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of eculizumab in Japan
jRCT2080224499Phase 3Completed
- Start
- Jan 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3 trial of eculizumab. Started Jan 2019; status: completed.
02
Drugs
eculizumab
Beyond the preview
Go deeper on jRCT2080224499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224499.